Literature DB >> 1503647

Fetal nuchal oedema: associated malformations and chromosomal defects.

K H Nicolaides1, G Azar, R J Snijders, C M Gosden.   

Abstract

During an 8-year period, oedema in the dorsal cervical region that produces a characteristic tremor on ballotement of the fetal head (nuchal oedema) was observed in 145 (7%) of the 2,086 fetuses that underwent karyotyping in our unit because of fetal malformations and/or growth retardation. Nuchal oedema was distinguished from nuchal cystic hygromata and from hydrops foetalis. In 132 (91%) of the cases with nuchal oedema, there were other fetal malformations, and 53 (37%) fetuses had chromosomal abnormalities, mainly trisomy 21 but also other trisomies, deletions or translocations, triploidy and Turner syndrome. Furthermore, the chromosomally normal fetuses with nuchal oedema had a very poor prognosis because, in many cases, there was an underlying skeletal dysplasia, a genetic syndrome or cardiac defect.

Entities:  

Mesh:

Year:  1992        PMID: 1503647     DOI: 10.1159/000263659

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  11 in total

1.  Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks' gestation.

Authors:  A F Brady; P P Pandya; B Yuksel; A Greenough; M A Patton; K H Nicolaides
Journal:  J Med Genet       Date:  1998-03       Impact factor: 6.318

Review 2.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

5.  Prenatal Diagnostic Value of Chromosomal Microarray in Fetuses with Nuchal Translucency Greater than 2.5 mm.

Authors:  Zhu Zhang; Ting Hu; Jiamin Wang; Qinqin Li; He Wang; Shanling Liu
Journal:  Biomed Res Int       Date:  2019-10-03       Impact factor: 3.411

Review 6.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 7.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

8.  Neurodevelopmental outcome at 2 years of corrected age in fetuses with increased nuchal translucency thickness and normal karyotype compared with matched controls.

Authors:  R Buffin; A Fichez; E Decullier; A Roux; S Bin; D Combourieu; B Pastor-Diez; C Huissoud; J-C Picaud
Journal:  Ultrasound Obstet Gynecol       Date:  2021-04-07       Impact factor: 7.299

9.  Ultrasound and echocardiographic findings obtained in the second and third trimesters of gestation in fetuses with normal karyotype and increased nuchal translucency.

Authors:  Hanna Moczulska; Katarzyna Janiak; Maciej Słodki; Maria Respondek-Liberska
Journal:  J Ultrason       Date:  2013-03-30

10.  A Chinese multicenter retrospective study of isolated increased nuchal translucency associated chromosome anomaly and prenatal diagnostic suggestions.

Authors:  Hua Jin; Juan Wang; Guoying Zhang; Hongyan Jiao; Jiansheng Zhu; Zhimin Li; Chen Chen; XuanPing Zhang; Huan Huang; JiaYin Wang
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.